Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTHENA CORPORATION PLC

(PRTA)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
58.12 USD   +2.49%
11/21Novo Nordisk Agrees to $40 Million Milestone Payment to Prothena
MT
11/21Prothena Achieves $40 Million Clinical Milestone Payment From Novo Nordisk
DJ
11/21Prothena Corp Public Ltd Co : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

RBC Lifts Price Target on Prothena to $52 From $45, Says Biogen/Eisai's Lecanemab Data Clear Way for Anti-Amyloid Drug Class in Alzheimer's; Outperform, Speculative Risk Kept

09/28/2022 | 08:08am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.17% 291.41 Delayed Quote.21.67%
PROTHENA CORPORATION PLC 2.49% 58.12 Delayed Quote.14.80%
All news about PROTHENA CORPORATION PLC
11/21Novo Nordisk Agrees to $40 Million Milestone Payment to Prothena
MT
11/21Prothena Achieves $40 Million Clinical Milestone Payment From Novo Nordisk
DJ
11/21Prothena Corp Public Ltd Co : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/21Prothena Corporation plc Announces Achievement of $40 Million Clinical Milestone Paymen..
CI
11/21Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nord..
BU
11/15Oppenheimer Adjusts Prothena Price Target to $120 From $110, Maintains Outperform Ratin..
MT
11/14Roche's Alzheimer's drug fails to meet goal in long awaited trial
RE
11/04Prothena : Corporate Overview
PU
11/04RBC Downgrades Prothena to Sector Perform From Outperform, Citing Valuation, Lifts Pric..
MT
11/03Prothena : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on PROTHENA CORPORATION PLC
More recommendations
Financials (USD)
Sales 2022 47,3 M - -
Net income 2022 -132 M - -
Net Debt 2022 - - -
P/E ratio 2022 -20,7x
Yield 2022 -
Capitalization 2 812 M 2 812 M -
Capi. / Sales 2022 59,4x
Capi. / Sales 2023 50,9x
Nbr of Employees 82
Free-Float 94,2%
Chart PROTHENA CORPORATION PLC
Duration : Period :
Prothena Corporation plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTHENA CORPORATION PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 58,12 $
Average target price 80,89 $
Spread / Average Target 39,2%
EPS Revisions
Managers and Directors
Gene G. Kinney President, Chief Executive Officer & Director
Tran B. Nguyen Chief Financial & Strategy Officer
Lars G. Ekman Chairman
Wagner M. Zago Head-Research
Hideki Garren Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTHENA CORPORATION PLC14.80%2 743
VERTEX PHARMACEUTICALS43.58%80 935
REGENERON PHARMACEUTICALS, INC.16.58%79 191
BIONTECH SE-37.36%39 245
WUXI APPTEC CO., LTD.-34.05%30 708
GENMAB A/S22.93%29 471